ERBB2 and breast cancer: Supporting this approach, recent findings from the RIGHT Choice trial showed that first-line ribociclib plus ET improved median PFS when compared with combination CHT, had comparable overall response rates (ORR) and lower rates of adverse events in HR+/HER2– advanced BC (29).